Saturday 17 October 2026
Export ANNX’s income statement to Excel — free account
Annexon, Inc.
ANNX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 17.7% and free cash flow fell 26.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.41
0.19
−5.28%
Follow ANNX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (105.26%) | (88.48%) | (82.63%) | (84.74%) |
+8 more TTM periods Free account |
|
| (79.38%) | (70.09%) | (66.45%) | (68.72%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(110.18%) | (97.97%) | (99.22%) | (130.23%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.96) | (0.94) | (1.20) | (1.18) | |
Free Cash Flow |
(193.23) | (183.10) | (186.49) | (176.59) | |
Capital Expenditures |
(0.20) | — | (0.14) | (0.14) | |
| Other line items | |||||
Cash ROIC |
(48.88%) | (42.62%) | (41.44%) | (50.43%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.95 | 0.92 | 0.89 | 0.84 | |
Depreciation/Fixed assets |
0.22 | 0.21 | 0.20 | 0.19 | |
Capex/Depreciation |
(0.09) | 0.00 | (0.06) | (0.07) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.96) | (0.94) | (1.20) | (1.18) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates